ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Expression Profile of Sphingosine Kinase 1 Isoforms in Human Cancer Tissues and Cells: Importance and Clinical Relevance of the Neglected 1b-Isoform

Chen, Hongjie; Haddadi, Nahal; Zhu, Xiaofeng; Hatoum, Diana; Chen, Size; Nassif, Najah T.; Lin, Yiguang*; McGowan, Eileen M.*广东药学院; 中山大学; 1
Journal of Oncology2022-12-7DOI: 10.1155/2022/2250407
3被引6阅读
引用收藏
分享

摘要

Background.Overexpression of sphingosine kinase 1 (SphK1) is casually associated with many types of cancer, and inhibitors of SphK1 sensitize tumors to chemotherapy. SphK1 is expressed as two major isoforms, SphK1a and SphK1b. To date, no information has been reported on the SphK1 isoform expression profile and its clinical relevance. Objective. The objective is to examine the expression profile of the SphK1a and SPhK1b isoforms in human cancer and noncancer tissues and cell lines and explore their clinical relevance. Methods. We used PCR to qualitatively examine the expression profile of these two isoforms in breast, liver, and prostate cancer tissues plus paired adjacent tissues and in 11 cancer and normal cell lines (breast, cervical, bone, prostate, colon, brain, mesothelioma tumor and benign, and human kidney cells). Results. We found that SphK1a was ubiquitously expressed in all cancer cells and tissues tested; in contrast, SphK1b was only expressed in selective cell types in breast, prostate, and lung cancer. Conclusions. Our data suggest that SphK1a is important for generic SphK1/S1P functions, and SphK1b mediates specialized and/or unique pathways in a specific type of tissue and could be a biomarker for cancer. This discovery is important for future SphK1-related cancer research and may have clinical implications in drug development associated with SphK1-directed cancer treatment.

学科与关键词

关键词
PROSTATE-CANCERBREAST-CANCERPROTEASOMAL DEGRADATION1-PHOSPHATE RECEPTORSINHIBITIONSPHINGOSINE-1-PHOSPHATEPOLYADENYLATIONSPHINGOLIPIDSREVEALSFTY720
相关
加载中…
  • Clinical Significance of Sphingosine Kinase-1 Expression in Human Astrocytomas Progression and Overall Patient Survival
    Li Jun; Guan Hong Yu; Gong Li Yun; Song Li Bing; Zhang Nu; Wu Jueheng; Yuan Jie; Zheng Yi Jie; Huang Zheng Song; Li Mengfeng*Clinical Cancer Research, 2008, 14(21): 6996-7003.被引 75
  • SphK1抑制剂的合成研究进展
    杨皓然; 柴会宁; 刘爱芹; 郑重飞; 刘波; 姚庆强化学研究, 2019, (04): 411-428.
  • Sphk1拮抗剂的研究进展
    杨皓然; 杨新美; 刘爱芹; 刘波; 姚庆强食品与药品, 2019, (05): 406-414.
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal of Oncology
发表日期
2022-12-07
卷期
第 2022 卷
页码
2250407
DOI
10.1155/2022/2250407
期刊等级
4区
成果收录
SCIE
资助标注
Science and Technology Program of Guangzhou, China; Science and Technology Planning Project of Guangdong Province of China; Guangdong Educational Committee Key Project of Regular Institutions of Higher Learning of Guangdong Province; [2018059]; [2010904010047]; [2019KZDXM024]

作者

  • C

    Chen, Hongjie (第一作者)

    sun yat sen univ

  • H

    Haddadi, Nahal

查看全部 8 位作者收起作者
  • Z

    Zhu, Xiaofeng

    1 · sun yat sen univ

  • H

    Hatoum, Diana

  • C

    Chen, Size

    1 · guangdong pharmaceut univ

  • N

    Nassif, Najah T.

  • L

    Lin, Yiguang (通讯)

    1 · guangdong pharmaceut univ · sun yat sen univ

  • M

    McGowan, Eileen M. (通讯)

    1 · guangdong pharmaceut univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417